|Bid||11.02 x 800|
|Ask||11.47 x 800|
|Day's Range||10.68 - 11.18|
|52 Week Range||9.21 - 20.62|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Patients in the trial will be randomized to receive either 12 mg twice-daily or 24 mg once-daily of CTP-543 over a 24 week treatment period. This new dose regimen trial is designed to complement the first open label trial initiated by Concert in March 2019, which is ongoing in patients randomized to receive either 8 mg twice-daily or 16 mg once-daily of CTP-543 over a 24 week treatment period.
Concert Pharmaceuticals, Inc. today announced that it will participate at the following upcoming investor conferences:
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Roger Tung has been the CEO of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) since 2006. Thi...
The Lexington, Massachusetts-based company said it had a loss of 93 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Concert Pharmaceuticals, Inc. (CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately. “We are delighted to welcome Jesper to our Board of Directors,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “He is a highly accomplished executive with current management experience as President and CEO of Radius Health, a biopharmaceutical company, and previously served as President and Executive Vice President, Novo Nordisk Inc. USA, where his expertise in product launches and management were instrumental in growing Novo to become the 15th largest pharmaceutical company worldwide.
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. A live webcast of the first quarter financial results may be accessed in the Investors section of the Company’s website at www.concertpharma.com.
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
Concert Pharmaceuticals, Inc. (CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11th Annual World Congress for Hair Research (WCHR) being held April 24-27, 2019 in Sitges, Barcelona.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 multiple-ascending dose trial will evaluate the safety, tolerability, and pharmacokinetic profile of CTP-692 in healthy volunteers. “The Phase 1 studies evaluating the dosing and safety of CTP-692 are expected to support advancement into an efficacy study in patients with schizophrenia later this year.
Shares of Concert Pharmaceuticals Inc. took a sharp afternoon dive Monday, after the biopharmaceutical company said the patent trial and appeal board found that the claims of the patent on its alopecia areata treatment CTP-543 were "not patentable." The stock, which was little changed in afternoon trade just prior to the announcement, plunged 17% toward a 2-year low after the announcement. The company said the decision was appealable to the U.S. court of appeals. "While we're disappointed in this outcome, we believe we have strong arguments supporting the validity of our patent and intend to appeal the decision as we work to create additional intellectual property protecting CTP-543," said Chief Executive Roger Tung. In April 2017, Incyte Corp. had filed a petition challenging the validity of the patent on CTP-543. Incyte's stock slipped 0.1%. Over the past 12 months, Concert's stock has tumbled 43%, Incyte shares have rallied 29%, the iShares Nasdaq Biotechnology ETF has climbed 13% and the S&P 500 has gained 11%.
Concert Pharmaceuticals, Inc. (CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149 patent). While PTAB found that the claims of the '149 patent are not patentable, the IPR decision is appealable to the U.S. Court of Appeals for the Federal Circuit, and Concert remains committed to defending the ‘149 patent.
Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019 at 1:00 p.m.
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is intended to inform the optimal dosing regimen for CTP-543 for future clinical trials. This open label trial follows the announcement of positive results from an interim analysis of an ongoing placebo-controlled Phase 2 trial that showed significant hair regrowth at 24 weeks with 8 mg twice-daily dosing of CTP-543.
Concert Pharmaceuticals, Inc. (CNCE) today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the late-breaking clinical trials session at the American Academy of Dermatology (AAD) Annual Meeting on March 2, 2019, in Washington, DC. The interim results from this dose-ranging trial showed that treatment with CTP-543 administered at an 8 mg twice-daily dose for 24 weeks met the primary endpoint with a statistically significant greater hair regrowth responder rate compared to placebo.
Significant Clinical Progress in 2018; Multiple Trials with Milestones in 2019
Concert Pharmaceuticals, Inc. today announced that it will report its financial results for the year ended December 31, 2018, on Thursday, February 28, 2019, before the U.S.